[go: up one dir, main page]

Agostini et al., 2015 - Google Patents

Blood Products, Derivates, and Prohemostatic Drugs

Agostini et al., 2015

View PDF
Document ID
14279763434041529600
Author
Agostini V
Santer P
Di Gregorio G
Tarzia V
Publication year
Publication venue
Point-of-Care Tests for Severe Hemorrhage: A Manual for Diagnosis and Treatment

External Links

Snippet

Blood Products, Derivates, and Prohemostatic Drugs | SpringerLink Skip to main content Advertisement Springer Nature Link Account Menu Find a journal Publish with us Track your research Search Cart 1.Home 2.Point-of-Care Tests for Severe Hemorrhage 3.Chapter Blood …
Continue reading at ndl.ethernet.edu.et (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Tanaka et al. Perioperative factor concentrate therapy
Levy et al. How I use fibrinogen replacement therapy in acquired bleeding
Levy et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy
Callum et al. Cryoprecipitate: the current state of knowledge
Nascimento et al. Cryoprecipitate therapy
Schulman Pharmacologic tools to reduce bleeding in surgery
Sniecinski et al. Bleeding and management of coagulopathy
Lier et al. Thromboelastometry guided therapy of severe bleeding
Sane et al. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management
Dickneite et al. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P)
Beshay et al. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients: a review
Ferreira et al. The clinical use of prothrombin complex concentrate
Chee et al. Management of bleeding in vascular surgery
Federici et al. Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study
Strauss et al. Perioperative management of rare coagulation factor deficiency states in cardiac surgery
Pandit et al. Blood component support in acquired coagulopathic conditions: is there a method to the madness?
Joseph et al. An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice
Figueiredo et al. Use of fresh frozen plasma: from the 2012 French guidelines to recent advances
Lewis et al. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage
Tobin et al. Factor concentrates in trauma
Mannucci et al. The use of plasma‐derived concentrates
Agostini et al. Blood Products, Derivates, and Prohemostatic Drugs
Downey et al. Effect of in vivo administration of fibrinogen concentrate versus cryoprecipitate on ex vivo clot degradation in neonates undergoing cardiac surgery
Sartori et al. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center
Asmis Coagulation factor concentrates